- Designation:Associate Professor
- Qualification:MD Radiotherapy
- Medical Council Registration: MP-3785
Dr. Veenita Yogi
- About Faculty: Dr. Veenita Yogi
- Education and Qualification:
Qualification/Degree Date College University MBBS 2000 SSMC Rewa APS University Rewa MD-Radiotherapy 2004 GMC BHOPAL Barkatulla University Bhopal - Work Experience:
Post Institution From To Total Years As Demonstrator/Tutor SR SSMC REWA 27/08/2004 28/02/2006 1 Year 6 Month As Assistant Professor GMC BHOPAL 03/03/2006 27/03/2018 12 Year As Associate Professor GMC BHOPAL 28/03/2018 Till Date 6 Year 4 Month Grand Total of Teaching Experience 19 Years 10 Month Detail of service/Working - working place/Institute name 2016 Assistant Professor, Department of Radiation Oncology, Gandhi Medical College, Bhopal 2017 Assistant Professor, Department of Radiation Oncology, Gandhi Medical College, Bhopal 2018 Designated Associate Professor, Department of Radiation Oncology, Gandhi Medical College, Bhopal 2019 Time Bound - Associate Professor, Department of Radiation Oncology, Gandhi Medical College, Bhopal 2020 Associate Professor, Department of Radiation Oncology, Gandhi Medical College, Bhopal 2021 Associate Professor, Department of Radiation Oncology, Gandhi Medical College, Bhopal - Publications:
Publications 1 Yogi V, Singh OP. Induction followed with concurrent chemoradiotherapy in advanced head & neck cancer. J Cancer Res Ther. 2005; 1(4): 198-203. PMID-17998653 PUBMED YES 2 Yogi V, Singh OP,Tiwari V. Malignant Chondroid Syringoma : A case report with review of literature.
RR: | Med Health Scien .2014; 3(2): 29-32.3 Tiwari V, Singh OP, Ghori HU, Yogi V.Peepre K,Yadav S. Assessment of treatment tolerance and response of elderly head and neck cancer patients: A single institution retrospective study. Clin Cancer lnvestig J. 2015; 4(3): 349. 4 Tiwari V, Singh OP, Ghori HU, Yogi V. Addressing the status of radiotherapy facilities in Bhopal: World leader in mouth cancers. Clin Cancer Investig J. 2015; 4(6):777. 5 Tiwari V , Yogi V ,Singh OP, Ghori HU. Identifying the factors causing delayed presentation of cancer patients to a Government Medical College of Central India. J Clin Diag Res.2015; 9(9):9-12 PMID-26500996 PUBMED YES 6 Ghori HU, Tiwari V, Singh OP, Yogi V,Shrivastava A, Mandloi V. Gemcitabine and cisplatin in metastatic carcinoma gall bladder : A single Institution retrospective analysis. J Dent Med Scien. 2015; 14(12):9-11. 7 Ghori HU, Tiwari V, Singh OP, Yogi V,Shrivastava A. Nab Paclitaxel and carboplatin as induction
chemotherapy in head and neck cancer patients: Efficacy and tolerability. J Dent Med Scien:2015; 14 (8):57-60.8 Shrivastava A, Mandloi V, Tiwari V, Ghori
HU, Singh OP, Yogi V. Nab Paclitaxe! as induction
chemotherapy in external auditory canal carcinoma : Case report and review of literature. Clin Cancer Investig J. 2016; 5(1): 76-78.9 Mandloi V, Shrivastava A, Ghori HU, Tiwari V, Singh OP , Yogi V. Carcinoma buccal mucosa in a treated case of carcinoma cervix : A rare presentation. Clin Cancer Investig J. 2016; 5(4):330 10 Tallari R, Yogi V Singh OP. Synchronous tuberculosis and breast cancer metastasis in axillary lymph nodes : A case report. Int J Scien Res.2016; 5(2): 319-20. 11 Tallari RV, Singh OP , Yogi V ,Yadav S. Five versus ten fractions per week radiotherapy in locallyadvanced head and neck cancer. | Cancer Res Ther2017; 13(2) :224-229. PMID-28643738 PUBMED YES 12 Shrivastava A, Ghori HU, Singh OP , Tiwari V, Yogi V. Comparison of toxicities associated with
concomitant boost and conventional fractionated radiotherapy regimen in oral and oropharyngeal
cancers. J Clin Diagn Res. 2017; 11(10): 1-5.13 Yogi V ,Singh OP, Malviya A, Ghori HU. Effect of post-operative time for adjuvant radiotherapy in
malignant phyllodes tumor.: An Institutional experience. JCancer Res Ther2018; Vol
14 (5):1054-1058.PMID=30197347 PUBMED YES14 Yogi..V._SinghOP..Ahirwar..M._Mandloi..V..Spectrum..of_cutaneous..metastasis.from.interoal
malienancies.¡_A.study of clinico-patholoRical and _survival.evaluation of.126. patients. Int.J Scien
Res.2018:.7(5) :206-208.15 Yogi. V. Lal N. Singh OP. Primary papillary adenocarcinoma.of.vagina:.a.rare malignancy. Int J Scien Res. 2018: 7(7): 35-36. 16 Shrivastava A, Yogi V ,Singh OP ,Mandloi V, Choudhary M. The symptom-to-treatment delay in
carcinoma cervix : Where we stand among developing countries. Int J Scien Res.2018; 7(9): 54-5617 Yogi V,Francis B, Singh OP ,Ahirwar M. Unilateral vocal cord paralysis in gastrointestinal malignancies-A rare presentation. International Journal of Scientific Research. 2018; 7 (11): 34-35. 18 Redhu P, Yogi V, Prajapati R, Singh OP. Orbital metastasis in Ewing's sarcoma : A rare cause of
proptosis. Int J Scien Res .2018; 7(11) : 60-61.19 Yogi V, Singh OP, Mandloi V, Ahirwar M. Role of Topical Aloe vera Gel in the Recovery of Higher grade Radiation -induced Dermatitis. Clin Cancer Investig J,2018; 7(5): 167-170. 20 Ahirwar. M..Yogi.V.. Singh.OP. .Ghori .M..Tiwari.V.Francis.B..Impact.of.Downstagins with.InductionChemotherapy. in Management of Locally. Advanced. Squamous Cell Carcinoma of Head andNeck.ClinCancer.Inyestig.1.2018;.7(6);221-226. 21 Yogi. V. Mani MP. Singh OP. Chori H. Atypical Presentation of Ewine's Sarcoma: Indian J Med PaediatrOncoL2019;40:51.09:13. 22 Yogi V, Singh OP. Effect of post-operative time for adjuvant radiotherapy in malignant phyllodes
tumor: An Institutional experience. J Cancer Res Ther. 2018 DOl: 10.4103/icrtJCRT_658_17 PUBMED YES23 Singh OP, Yogi V Redhu P ,Ghori HU, Pareek A, Lal N. Role of Serum Prostate-specific antigen as
Predictor for Bone Metastases in Newly Diagnosed Prostate cancer. J Cancer Res
Ther 2019;15:539-41.PMID-30900618 PUBMED YES24 Yogi V, Singh OP, Redhu P, Francis B. Impact of Sites of Involvement in Prognosis of Extranodal Non-Hodgkin lymphomas. Middle East J cancer. October 2019; 10(4):324-332. 25 Ahirwar M , Yogi V, Singh OP. A Randomized prospective comparative study of single versus
combination chemo-radiation in locally advanced head and neck cancers.Cancer Ther Oncol Int ] July2019; 14(3): 001-005.D0110.19080/CTONJ.2019.14.55589026 Yadav S, Chandel SS, Choudhary S, Yogi V, Singh OP, Dinesh KS , Goswami B. Dosimetric analysis of3D-CT image based high dose rate brachytherapy treatment planning of carcinoma uterine cervix: Initial
experiences at Central India Government Institute. ! Cancer Sci Ther 2019;11(8):244-250.27 Pareek A, Singh OP , Yogi V, Ghori HU, Tiwari V. Bone metastases incidence and its correlation with hormonal and Her?:ney receptors in breast cancer. | Cancer Res Ther 2019.DOI:10.4103/icrt.JCRI_235_18
PUBMED YES28 Yadav S, Singh OP, Choudhary S, Dinesh KS, Yogi V, Goswami B. Estimation and comparison of integral dose to target and organ at risks in 3D CT image based treatment planning of carcinoma uterine cervixwith two HDR brachytherapy sources : 60 Co 192 Ir. J Cancer ResTher.2020,DO1:10.4103/icrt.CRT_199_19PUBMED YES 29 Mandloi V, Yogi V, Singh OP, Ahirwar M, Yadav S, Ghori HU. A Comparative Study of NabPaclitaxel versus Cisplatin Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer. Clin Cancer Investig J.2019. DOI:10.4103/ccjj.sci_59_19 30 Yadav S, Yogi V et alInterfraction physical dose variations in high-dose-rate brachytherapy for carcinoma cervix based on computed tomography image dataset to find the compatibility of the first fraction plan to treat successive fractions .December 2019 . Journal of Cancer Research and Therapeutics PUBMED YES 31 Yogi V , et alDosimetric comparison of two type's applicator geometry in the three-dimensional computed tomography image-based intracavitary brachytherapy treatment planning of carcinoma uterine February 2021 . Journal of Radiation and Cancer Research 32 Yogi V, Chandel SS, Yadav S, Singh OP, Goswami B, Ghosh G, Choudhary S. Dosimetric comparison of two type’s applicator geometry in the three-dimensional computed tomography image-based intracavitary brachytherapy treatment planning of carcinoma uterine cervix. J Radiat Cancer Res. 2021;12 (1).[DOAJ] 33 Lal N, Yadav S, Yogi V, Singh OP, Ghori HU, Choudhary M, et al. Evaluation of Dose-Volume –Based Image- Guided High-Dose-Rate-Brachytherapy in Carcinoma Uterine Cervix: A Prospective Study .J Radiat Cancer Res. 2022;13 (1). [DOAJ}
34 Uikey G, Ahirwar H, Kori R, Yogi V, Yadav S, Singh OP et al. Metastatic trends in breast cancer according to molecular subtypes, estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2neu status. J Med Scien Health. 2022 ;8(2):100-105. [DOAJ}
35 Saxena R, Singh OP, Yogi V, Yadav S, Pathak PK, Ghori HU, Tiwari V, Choudhary M, Saxena s.Prospective Study to Evaluate the Dosimetric Profile of Organ at Risk in Two Field and Three Field Left Breast Irradiation by 3-Dimensional Conformal Radiotherapy. Turkish J Oncol. 2022 [SCOPUS, EMBASE]
36 Choudhary M, Yogi V, Saxena S, Gupta V, Singh OP, Yadav S, Saxena R. Comparison of thyroid toxicity profile in head and neck cancer patients irradiated by 3D-conformal radiation therapy and intensity modulated radiation therapy. Med J DY Patil Vidyapeeth 2022; [SCOPUS, DOAJ]
- Other Details:
Enlist the topic Covered in last one year 1 Radiobiology 2 Radiotherapy Planning 3 Basic principles of radiotherapy 4 Oncological emergencies 5 Basic principles of chemotherapy 6 Clinical Oncology 7 Stage-wise management of malignancies ( Head & neck, breast, lung, Gastro intestinal, genitourinary, sarcoma, lymphomas, leukaemia, skin) 8 Paediatric malignancie 9 Particulate radiation therapy 10 Brachytherapy planning